Gland Pharma

₹1764.4 55.8 | 3.3%

WEBSITE BSE:543245 NSE : GLAND 13 May, 16:12

Market Cap ₹29062 Cr.

Stock P/E 44.1

P/B 3.4

Current Price ₹1764.4

Book Value ₹ 516

Face Value 1

52W High ₹2195.8

Dividend Yield 0%

52W Low ₹ 861.5

Edit Ratio

Gland Pharma Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Gland Pharma Ltd engages in the development, manufacture, and marketing of injectable-focused widespread liquid parental merchandise. The agency's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its merchandise below diverse therapeutic categories, which include anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, ache management, hormones and associated tablets, fertility dietary supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, breathing, blood related, ophthalmological and otological, ache/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The business enterprise additionally affords contract improvement services. It sells its products mainly under a business to business in the United States, Europe, Canada, Australia, India, and across the world. The enterprise incorporated in 1978 and is based in Hyderabad, India.

Gland Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Gland Pharma Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	1080	1063	1103	857	1044	938	785	1209	1373	1545
Other Income	51	46	65	74	66	62	39	38	53	37
Total Income	1132	1109	1168	931	1110	1000	824	1246	1427	1583
Total Expenditure	704	714	755	587	748	649	617	915	1049	1189
Operating Profit	428	395	414	344	362	351	207	331	377	394
Interest	1	1	2	1	2	3	2	5	6	5
Depreciation	26	28	31	35	37	38	38	65	81	105
Exceptional Income / Expenses	0	0	0	0	0	0	-56	0	0	0
Profit Before Tax	401	366	380	308	324	311	111	261	290	283
Provision for Tax	99	93	95	79	83	79	32	67	96	91
Profit After Tax	302	273	286	229	241	232	79	194	194	192
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	302	273	286	229	241	232	79	194	194	192
Adjusted Earnings Per Share	18.4	16.6	17.4	13.9	14.6	14.1	4.8	11.8	11.8	11.6

Gland Pharma Profit & Loss

#(Fig in Cr.)	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	2633	3463	4401	3625	4912
Other Income	139	135	224	240	167
Total Income	2772	3598	4625	3865	5080
Total Expenditure	1678	2161	2891	2600	3770
Operating Profit	1095	1437	1734	1265	1309
Interest	7	3	5	7	18
Depreciation	95	99	110	147	289
Exceptional Income / Expenses	0	0	0	-56	-56
Profit Before Tax	993	1335	1619	1055	945
Provision for Tax	220	338	407	274	286
Profit After Tax	773	997	1212	781	659
Adjustments	0	0	0	0	0
Profit After Adjustments	773	997	1212	781	659
Adjusted Earnings Per Share	49.9	60.9	73.7	47.4	40

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	-18%	11%	0%	0%
Operating Profit CAGR	-27%	5%	0%	0%
PAT CAGR	-36%	0%	0%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	29%	-15%	NA%	NA%
ROE Average	10%	17%	18%	18%
ROCE Average	14%	22%	24%	24%

Gland Pharma Balance Sheet

#(Fig in Cr.)	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	3646	5903	7158	7959
Minority's Interest	0	0	0	0
Borrowings	4	4	4	3
Other Non-Current Liabilities	77	76	90	86
Total Current Liabilities	359	513	582	729
Total Liabilities	4086	6496	7834	8778
Fixed Assets	968	954	1502	1571
Other Non-Current Assets	272	418	479	306
Total Current Assets	2846	5124	5852	6901
Total Assets	4086	6496	7834	8778

Gland Pharma Cash Flow

#(Fig in Cr.)	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	236	169	492	319
Cash Flow from Operating Activities	701	605	791	364
Cash Flow from Investing Activities	-766	-1524	-1003	1208
Cash Flow from Financing Activities	-7	1238	35	15
Net Cash Inflow / Outflow	-72	319	-177	1587
Closing Cash & Cash Equivalent	169	492	319	1909

Gland Pharma Ratios

#	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	49.88	60.94	73.75	47.42
CEPS(Rs)	55.98	66.98	80.46	56.33
DPS(Rs)	0	0	0	0
Book NAV/Share(Rs)	234.25	359.3	434.84	483.12
Core EBITDA Margin(%)	36.28	37.61	34.32	28.27
EBIT Margin(%)	37.98	38.64	36.9	29.3
Pre Tax Margin(%)	37.71	38.55	36.78	29.1
PAT Margin (%)	29.35	28.79	27.53	21.55
Cash Profit Margin (%)	32.94	31.64	30.04	25.6
ROA(%)	18.91	18.84	16.91	9.4
ROE(%)	21.29	20.97	18.61	10.34
ROCE(%)	27.39	28	24.85	14.04
Receivable days	83.41	67.08	72.4	97.99
Inventory Days	104.83	107.06	102.05	157.65
Payable days	108.75	96.63	74.34	113.72
PER(x)	0	40.66	44.33	26.75
Price/Book(x)	0	6.9	7.52	2.63
Dividend Yield(%)	0	0	0	0
EV/Net Sales(x)	-0.5	10.84	11.5	4.73
EV/Core EBITDA(x)	-1.19	26.12	29.19	13.54
Net Sales Growth(%)	0	31.51	27.08	-17.64
EBIT Growth(%)	0	33.82	21.34	-34.6
PAT Growth(%)	0	29	21.54	-35.54
EPS Growth(%)	0	22.18	21.01	-35.7
Debt/Equity(x)	0	0	0	0
Current Ratio(x)	7.93	10	10.05	9.46
Quick Ratio(x)	5.82	7.51	8.02	6.8
Interest Cover(x)	139.24	392.33	309.77	142.61
Total Debt/Mcap(x)	0	0	0	0

Gland Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	58	58	57.87	57.86	57.86	57.86	57.86	57.86	57.86	57.86
FII	11.3	10.72	9.41	6.09	4.66	4.32	2.8	4.91	4.04	3.59
DII	11.66	12.46	17.37	21.91	23.13	23.24	23.38	22.45	24.17	25.23
Public	19.05	18.82	15.35	14.13	14.34	14.58	15.96	14.78	13.93	13.32
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	9.53	9.53	9.53	9.53	9.53	9.53	9.53	9.53	9.53	9.53
FII	1.86	1.76	1.55	1	0.77	0.71	0.46	0.81	0.67	0.59
DII	1.92	2.05	2.86	3.61	3.81	3.83	3.85	3.7	3.98	4.16
Public	3.13	3.09	2.53	2.33	2.36	2.4	2.63	2.44	2.29	2.19
Others	0	0	0	0	0	0	0	0	0	0
Total	16.43	16.43	16.47	16.47	16.47	16.47	16.47	16.47	16.47	16.47

Pros

Company has reduced debt.
Company is almost debt free.

Cons

Debtor days have increased from 74.34 to 113.72days.
Stock is trading at 3.4 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Gland Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Gland Pharma

Add Watchlist

Gland Pharma Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Gland Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Gland Pharma Quarterly Results

Gland Pharma Profit & Loss

Growth Rates

Gland Pharma Balance Sheet

Gland Pharma Cash Flow

Gland Pharma Ratios

Gland Pharma Shareholding Pattern

Gland Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!